Skip to main content

2022 CTOS Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Scott Schuetze, MD, PhD

Department of Internal Medicine, University of Michigan, Rogel Cancer Center

Poster(s):

(P 314) A PHASE II/III, RANDOMIZED, OPEN LABEL, MULTICENTER STUDY OF THE MDM2–P53 ANTAGONIST BI 907828 VS DOXORUBICIN IN THE FIRST-LINE TREATMENT OF PATIENTS WITH DEDIFFERENTIATED LIPOSARCOMA: BRIGHTLINE-1